Volume 23, Number 1—January 2017
CME ACTIVITY - Research
Analysis of Anthrax Immune Globulin Intravenous with Antimicrobial Treatment in Injection Drug Users, Scotland, 2009–2010
Figure 3
![Individual LF levels (nanograms per milliliter) in 12 anthrax patients receiving AIG-IV from 10 h before until 50 h after treatment administration, Scotland, UK, 2009–2010. AIG-IV, anthrax immune hlobulin intravenous; LF, lethal factor.](/eid/images/16-0608-F3.jpg)
Figure 3. Individual LF levels (nanograms per milliliter) in 12 anthrax patients receiving AIG-IV from 10 h before until 50 h after treatment administration, Scotland, UK, 2009–2010. AIG-IV, anthrax immune hlobulin intravenous; LF, lethal factor.
1These authors contributed equally to this article.
Page created: December 14, 2016
Page updated: December 14, 2016
Page reviewed: December 14, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.